Triangular test design to evaluate tinidazole in the prevention of Plasmodium vivax relapse

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Macareo, Louis ^a   Lwin, Khin Maung ^b,c   Cheah, Phaik Yeong ^c,d   Yuentrakul, Prayoon ^c   Miller, R Scott ^a   Nosten, Francois ^b,c,d  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Malaria; Plasmodium vivax; Relapse; Sequential analysis; Tinidazole; Triangular test

Indexed keywords

CHLOROQUINE; PRIMAQUINE; TINIDAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; DRUG COST; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MALE; NONHUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PARASITE CLEARANCE; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; RELAPSE; SEQUENTIAL ANALYSIS; STUDY DESIGN; TRIANGULAR TEST;

ADULT; ANTIMALARIALS; CHEMOPREVENTION; CHLOROQUINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALARIA, VIVAX; MALE; MYANMAR; PARASITE LOAD; PARASITEMIA; RECURRENCE; THAILAND; TINIDAZOLE; TREATMENT OUTCOME;

EID: 84878223099     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-173     Document Type: Article

References (20)

1. Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand. Buchachart K, Krudsood S, Singhasivanon P, Treeprasertsuk S, Phophak N, Srivilairit S, Chalermrut K, Rattanapong Y, Supeeranuntha L, Wilairatana P, Brittenham G, Looareesuwan S, Southeast Asian J Trop Med Public Health 2001 32 720 726 12041544
2. The hemolytic effect of primaquine and related compounds: a review. Beutler E, Blood 1959 14 103 139 13618370
3. Biochemical and genetic aspects of primaquine-sensitive hemolytic anemia. Alving AS, Kellermeyer RW, Tarlov A, Schrier S, Carson PE, Ann Intern Med 1958 49 240 248 13571815
4. Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline. Bolchoz LJ, Budinsky RA, McMillan DC, Jollow DJ, J Pharmacol Exp Ther 2001 297 509 515 11303037
5. Appraisals of compounds of diverse chemical classes for capacities to cure infections with sporozoites of Plasmodium cynomolgi. Schmidt LH, Am J Trop Med Hyg 1983 32 231 257 6837838
6. Triangular test applied to the clinical trial of azithromycin against relapses in Plasmodium vivax infections. Ranque S, Badiaga S, Delmont J, Brouqui P, Malar J 2002 1 13 10.1186/1475-2875-1-13 12473182
7. Effects of perioperative intravenous low dose of ketamine on postoperative analgesia in children. Bazin V, Bollot J, Asehnoune K, Roquilly A, Guillaud C, De Windt A, Nguyen JM, Lejus C, Eur J Anaesthesiol 2010 27 47 52 19535988
8. Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Omollo R, Alexander N, Edwards T, Khalil EA, Younis BM, Abuzaid AA, Wasunna M, Njoroge N, Kinoti D, Kirigi G, Dorlo TP, Ellis S, Balasegaram M, Musa AM, Trials 2011 12 166 10.1186/1745-6215-12-166 21718522
9. FDA, Tinidazole drug label: FDA 2007 http://www.accessdata.fda.gov/ drugsatfda-docs/label/2007/021618s003lbl.pdf
10. Micromedex®2.0, Drugdex® evaluation for Tinidazole: Truven Health Analytics 2013 http://www.micromedexsolutions.com 23489131
11. Use of Rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances. Deye G, Gettayacamin M, Pranee H, Im-erbsin R, Sattabongkot J, Rothstein Y, Macareo L, Fracisco S, Bennett K, Magill A, Ohrt C, Am J Trop Med Hyg 2012 86 931 935 10.4269/ajtmh.2012.11-0552 22665596
12. Tinidazole: a new drug in the treatment of vivax malaria. Sarma P, Curr Ther Res 1988 43 3
13. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Goller JL, Jolley D, Ringwald P, Biggs BA, Am J Trop Med Hyg 2007 76 203 207 17297026
14. Treatment of vivax malaria on the western border of Thailand. Luxemburger C, van Vugt M, Jonathan S, McGready R, Looareesuwan S, White NJ, Nosten F, Trans R Soc Trop Med Hyg 1999 93 433 438 10.1016/S0035-9203(99)90149-9 10674098
15. Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Pukrittayakamee S, Imwong M, Looareesuwan S, White NJ, Acta Trop 2004 89 351 356 10.1016/j.actatropica.2003.10.012 14744561
16. Primaquine-tolerant vivax malaria in Thailand. Looareesuwan S, Buchachart K, Wilairatana P, Chalermrut K, Rattanapong Y, Amradee S, Siripiphat S, Chullawichit S, Thimasan K, Ittiverakul M, Triampon A, Walsh DS, Ann Trop Med Parasitol 1997 91 939 943 9579214
17. Chloroquine sensitivity of Plasmodium vivax in Thailand. Looareesuwan S, Wilairatana P, Krudsood S, Treeprasertsuk S, Singhasivanon P, Bussaratid V, Chokjindachai W, Viriyavejakul P, Chalermrut K, Walsh DS, White J, Ann Trop Med Parasitol 1999 93 225 230 10.1080/00034989958474 10562823
18. Application of the triangular test to phase II cancer clinical trials. Bellissant E, Benichou J, Chastang C, Stat Med 1990 9 907 917 10.1002/sim.4780090807 2218193
19. [Design and analysis of phase II trials in oncology with a group sequential method, the triangular test] (in French). Bellissant E, Benichou J, Chastang C, Therapie 1991 46 21 27 2020920
20. The R Project for Statistical Computing http://www.R-project.org